CytoCore Solutions System

Related by string. * : substantiate CytoCore expectations . CytoCore develops cost . law CytoCore undertakes . CytoCore Solutions / solu tions . SOLUTION . solutions . SOLUTIONS : Customer Interaction Solutions . Supply Chain Solutions . Twisted Pair Solutions . IS.eFinance Solutions powered / SYSTEM . SYSTEMS . system : Systems Network FEWS . Blue Coat Systems . Global Positioning System * *

Related by context. Frequent words. (Click for all words.) 63 TranSwitch indebtedness 56 Bioenvision compounds under 55 WHICH ARE NOT PURELY 55 R sorafenib tablets 55 PREZISTA r 54 HISTORICAL ARE FORWARD LOOKING 54 TranSwitch filings 54 * Potentially libelous 53 Therein lurks 53 suchforward looking 53 Hill Rom enhancing 53 y h 52 XML UDDI Universal 52 inflammatory autoimmune diseases 52 involving hydrophilic liquid 52 ACTUAL RESULTS COULD DIFFER 52 SAFE HARBOR PROVISIONS OF 52 y u 52 ENTIRETY BECAUSE THEY CONTAIN 52 Lexicon undertakes 51 h g 51 OR SIMILAR STATEMENTS ARE 51 FUNDING AS WELL AS 51 MGCD# MGCD# [001] 51 hypercalcemia 51 referenced investigational 51 h u 51 Acorda Therapeutics filings 51 OF THE SUBSTANCE 51 colorectal lung 51 forward.looking statements 51 nonoccurrence 50 Ratings Synopsis 50 EDGAR Online Guide 50 Cytogen periodic filings 50 AS ESTIMATE ANTICIPATE BELIEVE 50 non personalized allogeneic 50 ManTech Annual Report 50 hospitals physicians homecare 50 By Thomas Gryta 50 While Ambrilia anticipates 50 LIMITATION MAY NOT APPLY 50 EpiCept periodic reports 50 STATEMENTS AND 50 www.norsat.com 50 UNITED STATES SECURITIES ACT 50 BioSante undertakes 50 BioSante licensees 50 Trofex 50 APTIVUS r 50 ELADUR 50 headings Forward Looking 50 Neuradiab 50 consummating acquisitions 50 IN OTHER PUBLICLY 50 GearUpForSports makes 50 ALTROPANE 50 THE RISKS SHOWN 50 HYPOTHETICAL OR SIMULATED PERFORMANCE 49 tumor lysis syndrome 49 Please respond insightfully 49 PINNACLEDIGEST.COM S PAST PERFORMANCE 49 I. Item 1A 49 viii insufficient 49 estimated metallurgical recoveries 49 EOD data 49 Powerwave Powerwave Technologies 49 ATK undertakes 49 i g 49 intents beliefs 49 SILENOR ™ 49 Sodium oxybate 49 By Laurelle Gilbert 49 Safe Harbor Disclosure 49 RR Donnelley disclaims 49 AND SHOULD ALSO 49 risks anduncertainties 49 Atheros disclaims 49 BY THESE FORWARD 49 pusporte 49 n h 49 h y 49 theSecurities 49 Internal quotation marks 49 Condition Classification 49 strontium ranelate 49 affecting Amarin 49 PolyMedix filings 49 immunohistochemical 49 PLAN OR EXPECT 49 renal flare 49 THE REPORTING 48 Alnylam dependence 48 APOPTONE 48 u t 48 Novavax cautions 48 THE EXPRESSED WRITTEN CONSENT 48 radiotherapy radiosurgery proton therapy 48 rheumatoid arthritis lupus 48 SAFE HARBOR Certain 48 party VLSI fabrication

Back to home page